Atractylodes chinensis volatile oil up-regulated IGF-1 to improve diabetic gastroparesis in rats.

Hongzeng Li, Yitong Wang, Yuxin Tian, Feiyue Tian, Zhiyang Xing, Yunfei Wang, Meixing Yan, Yanling GongPubMed 2022 · DOI

TL;DR

This study investigates the therapeutic potential of Atractylodes chinensis volatile oil (ACVO) for diabetic gastroparesis (DGP) in rats. ACVO demonstrated a significant improvement in gastric emptying and intestinal propulsion, likely by up-regulating the IGF-1/IGF-1R signaling pathway, which in turn influences key cellular components involved in gut motility.

What Problem Does This Paper Address?

Diabetic gastroparesis (DGP) is a debilitating complication of diabetes, affecting a significant portion of patients and severely impacting their quality of life. Current treatments, while helpful, often come with adverse side effects, highlighting the need for novel therapeutic agents with better safety profiles. DGP is characterized by delayed gastric emptying and impaired intestinal motility, which are intricately linked to the proper functioning of interstitial cells of Cajal (ICCs) and neurotransmitter signaling. While the role of insulin-like growth factor 1 (IGF-1) in neuronal health and cell growth is known, its specific involvement in DGP and the potential of natural compounds to modulate this pathway for therapeutic benefit remained underexplored. This paper aims to fill this gap by examining the efficacy of ACVO, a traditional Chinese medicine component, in treating DGP and elucidating its underlying molecular mechanisms.

Methods

The researchers established a rat model of diabetic gastroparesis by administering streptozotocin (STZ) combined with a high-sugar, high-fat diet. This model mimics key features of DGP, including hyperglycemia and impaired gastric function.

The core experimental techniques employed were:

  • Drug Administration: Rats were treated with varying doses of ACVO (low, medium, high) or a combination of cisapride and metformin (positive control) via intragastric gavage.
  • Gastric Emptying and Intestinal Propulsion Assays: A phenolic red solution was used as a marker to quantitatively assess how quickly stomach contents moved into the intestines and how far along the intestines the marker traveled.
  • Biochemical Assays:
    • Fasting Blood Glucose and Body Weight: Monitored to confirm the establishment of the diabetes model and assess the overall metabolic impact of ACVO.
  • Serum IGF-1 Levels: Measured using ELISA kits to quantify the circulating levels of IGF-1.
  • Gastric Acid Secretion and Gastric Juice Volume: Determined by titrating gastric juice with NaOH.
  • Molecular and Cellular Analysis:
    • Western Blotting: Used to measure the protein expression levels of key molecules in gastric tissue, including IGF-1 receptor (IGF-1R), acetylcholine transferase (CHAT), and stem cell factor (SCF). GAPDH was used as a loading control.
  • Immunohistochemical Staining: Employed to visualize and quantify the presence of ICCs in gastric tissue using an antibody against c-Kit.
  • Immunofluorescence Staining: Used to assess the expression and localization of IGF-1R, CHAT, and SCF within the gastric tissue.
  • Hematoxylin and Eosin (H&E) Staining: Performed to examine the overall morphology and cellular structure of the gastric tissue.

The study employed standard statistical methods, including one-way ANOVA, to analyze the data and determine significant differences between groups.

Datasets

Not discussed in the paper. The study utilized experimental animal models and collected biological samples for analysis.

Key Insights and Ideas

  • ACVO as a Promising Therapeutic for DGP: The study provides strong evidence that ACVO can effectively alleviate symptoms of diabetic gastroparesis in a rat model, offering a potential natural alternative to existing treatments.
  • IGF-1 Signaling as a Central Mechanism: The findings strongly implicate the IGF-1/IGF-1R pathway as a critical mediator of ACVO's therapeutic effects. Upregulation of this pathway appears to be a key driver in restoring gastric function.
  • Restoration of ICCs is Crucial: The research highlights the direct link between ACVO's action and the restoration of interstitial cells of Cajal (ICCs). ICCs are the "pacemakers" of the gut, and their depletion is a hallmark of DGP. ACVO's ability to increase ICC numbers is a significant finding.
  • Synergistic Effects on Gut Motility Components: ACVO not only impacts IGF-1 signaling but also positively influences other key players in gut motility, such as CHAT (involved in neurotransmission) and SCF (essential for ICC maintenance and differentiation). This suggests a multi-faceted approach by ACVO.
  • Dose-Dependent Efficacy: The observed improvements in various parameters (body weight, blood glucose, gastric emptying, etc.) were dose-dependent, indicating a clear biological response to increasing concentrations of ACVO.

Key Results

  • Improved Metabolic Parameters: ACVO treatment led to increased body weight and decreased blood glucose levels in DGP rats, suggesting a broader metabolic benefit beyond just gastric function.
  • Enhanced Gastric Motility: ACVO significantly accelerated gastric emptying and intestinal propulsion in DGP rats, reversing the delays characteristic of the condition.
  • Restored Gastric Secretion: Gastric acid secretion and gastric juice volume were also improved by ACVO treatment.
  • Elevated Serum IGF-1: ACVO treatment significantly increased serum IGF-1 levels in a dose-dependent manner.
  • Upregulated Protein Expression: ACVO upregulated the protein expression of IGF-1R, CHAT, and SCF in gastric tissues of DGP rats.
  • Increased ICCs: Immunofluorescence and immunohistochemical staining revealed a significant increase in the number of ICCs in the gastric tissues of ACVO-treated rats.
  • Histological Improvement: H&E staining showed that ACVO treatment restored the normal morphology of gastric tissue in DGP rats.

Limitations and Future Work

Limitations:

  • Animal Model: While the STZ-induced diabetes model is widely used, it may not perfectly replicate the complexity of human diabetic gastroparesis, which can involve various underlying mechanisms and comorbidities.
  • Mechanism Specificity: While the study strongly suggests the IGF-1/IGF-1R pathway is involved, further research could explore other potential signaling cascades that ACVO might influence.
  • Human Translation: The findings are based on rat studies, and further preclinical and clinical trials are necessary to confirm ACVO's efficacy and safety in humans.

Future Work:

  • In-depth Mechanistic Studies: Further investigation into the precise molecular interactions and downstream targets of the IGF-1/IGF-1R pathway modulated by ACVO.
  • Exploration of Other Components: Identifying the specific active compounds within ACVO responsible for these therapeutic effects.
  • Long-term Efficacy and Safety: Conducting studies to assess the long-term benefits and potential side effects of ACVO in more complex models or in human trials.
  • Combination Therapies: Investigating the potential synergistic effects of ACVO with other therapeutic agents for DGP.

Summary updated

Abstract

ACVO effectively alleviated DGP in rats, and its mechanism may be related to the up-regulation of IGF-1/IGF-1R signaling.
BibTeX
@inproceedings{li2022i,
  author = {Hongzeng Li and Yitong Wang and Yuxin Tian and Feiyue Tian and Zhiyang Xing and Yunfei Wang and Meixing Yan and Yanling Gong},
  title = {{<i>Atractylodes chinensis</i> volatile oil up-regulated IGF-1 to improve diabetic gastroparesis in rats.}},
  booktitle = {PubMed},
  year = {2022},
  doi = {10.22038/ijbms.2022.60126.13339},
}
Figure